相似文献
1
Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?
Arch Med Res. 2020 May;51(4):345-346. doi: 10.1016/j.arcmed.2020.03.011. Epub 2020 Apr 4.
2
Angiotensin Converting Enzyme-2 (ACE2) Receptors, asthma and severe COVID-19 infection risk.
Eur Ann Allergy Clin Immunol. 2020 Nov;52(6):282-285. doi: 10.23822/EurAnnACI.1764-1489.169. Epub 2020 Nov 3.
3
Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system?
Hypertens Res. 2020 Aug;43(8):854-856. doi: 10.1038/s41440-020-0476-3. Epub 2020 May 22.
4
Oral submucous fibrosis and COVID-19: Perspective on comorbidity.
Oral Oncol. 2020 Aug;107:104811. doi: 10.1016/j.oraloncology.2020.104811. Epub 2020 May 21.
5
[ACE2 and coronavirus - a question of balance and dynamics?].
Lakartidningen. 2020 Apr 17;117:F3S3.
6
Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection.
Am J Physiol Heart Circ Physiol. 2020 Nov 1;319(5):H1059-H1068. doi: 10.1152/ajpheart.00681.2020. Epub 2020 Oct 9.
7
Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
Drug Discov Ther. 2020;14(4):161-170. doi: 10.5582/ddt.2020.03064.
8
ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
Clin Sci (Lond). 2020 Nov 13;134(21):2791-2805. doi: 10.1042/CS20200484.
9
The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies.
J Appl Physiol (1985). 2020 Oct 1;129(4):864-867. doi: 10.1152/japplphysiol.00321.2020. Epub 2020 Jul 16.
10
COVID-19 infection: ACE2, pregnancy and preeclampsia.
Eur J Obstet Gynecol Reprod Biol. 2020 Oct;253:330. doi: 10.1016/j.ejogrb.2020.08.007. Epub 2020 Aug 22.
引用本文的文献
1
Assessment of Female Hormonal Influence on COVID-19 Vaccine Response: A Prospective Cohort Study.
Cureus. 2024 Feb 18;16(2):e54417. doi: 10.7759/cureus.54417. eCollection 2024 Feb.
2
Developmental Impacts of Epigenetics and Metabolism in COVID-19.
J Dev Biol. 2024 Feb 9;12(1):9. doi: 10.3390/jdb12010009.
3
Genetic and Epigenetic Determinants of COVID-19 Susceptibility: A Systematic Review.
Curr Med Chem. 2025;32(4):753-770. doi: 10.2174/0109298673267890231221100659.
4
miRNAs: The Key Regulator of COVID-19 Disease.
Int J Cell Biol. 2022 Oct 29;2022:1645366. doi: 10.1155/2022/1645366. eCollection 2022.
5
Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications.
Nat Rev Gastroenterol Hepatol. 2023 May;20(5):323-337. doi: 10.1038/s41575-022-00698-4. Epub 2022 Oct 21.
6
SARS-COV-2 as potential microRNA sponge in COVID-19 patients.
BMC Med Genomics. 2022 Apr 23;15(Suppl 2):94. doi: 10.1186/s12920-022-01243-7.
7
Implications of the Immune Polymorphisms of the Host and the Genetic Variability of SARS-CoV-2 in the Development of COVID-19.
Viruses. 2022 Jan 6;14(1):94. doi: 10.3390/v14010094.
8
New Onset of Autoimmune Diseases Following COVID-19 Diagnosis.
Cells. 2021 Dec 20;10(12):3592. doi: 10.3390/cells10123592.
9
An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19.
Curr Res Pharmacol Drug Discov. 2021;2:100063. doi: 10.1016/j.crphar.2021.100063. Epub 2021 Oct 8.
10
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.
Expert Opin Drug Saf. 2021 Nov;20(11):1309-1315. doi: 10.1080/14740338.2021.1970744. Epub 2021 Aug 25.
本文引用的文献
1
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
2
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
3
Epidemiology of Cardiovascular Disease in China and Opportunities for Improvement: JACC International.
J Am Coll Cardiol. 2019 Jun 25;73(24):3135-3147. doi: 10.1016/j.jacc.2019.04.036.
4
MERS transmission and risk factors: a systematic review.
BMC Public Health. 2018 May 2;18(1):574. doi: 10.1186/s12889-018-5484-8.
5
Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015.
Circulation. 2018 May 29;137(22):2344-2356. doi: 10.1161/CIRCULATIONAHA.117.032380. Epub 2018 Feb 15.
6
A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly.
Aging Dis. 2018 Feb 1;9(1):143-150. doi: 10.14336/AD.2017.0306. eCollection 2018 Feb.
7
Middle East respiratory syndrome.
Lancet. 2015 Sep 5;386(9997):995-1007. doi: 10.1016/S0140-6736(15)60454-8. Epub 2015 Jun 3.
8
China type 2 diabetes treatment status survey of treatment pattern of oral drugs users.
J Diabetes. 2015 Mar;7(2):166-73. doi: 10.1111/1753-0407.12165. Epub 2014 Aug 7.
9
Hypertension control in community health centers across China: analysis of antihypertensive drug treatment patterns.
Am J Hypertens. 2014 Feb;27(2):252-9. doi: 10.1093/ajh/hpt186. Epub 2013 Oct 9.
10
Prevalence and control of diabetes in Chinese adults.
JAMA. 2013 Sep 4;310(9):948-59. doi: 10.1001/jama.2013.168118.
Zotero 插件